122 related articles for article (PubMed ID: 15621687)
1. Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo.
Bartsch M; Weeke-Klimp AH; Hoenselaar EP; Stuart MC; Meijer DK; Scherphof GL; Kamps JA
J Drug Target; 2004; 12(9-10):613-21. PubMed ID: 15621687
[TBL] [Abstract][Full Text] [Related]
2. Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells.
Bartsch M; Weeke-Klimp AH; Meijer DK; Scherphof GL; Kamps JA
Pharm Res; 2002 May; 19(5):676-80. PubMed ID: 12069172
[TBL] [Abstract][Full Text] [Related]
3. Optimized targeting of polyethylene glycol-stabilized anti-intercellular adhesion molecule 1 oligonucleotide/lipid particles to liver sinusoidal endothelial cells.
Bartsch M; Weeke-Klimp AH; Morselt HW; Kimpfler A; Asgeirsdóttir SA; Schubert R; Meijer DK; Scherphof GL; Kamps JA
Mol Pharmacol; 2005 Mar; 67(3):883-90. PubMed ID: 15598973
[TBL] [Abstract][Full Text] [Related]
4. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems.
Islam A; Handley SL; Thompson KS; Akhtar S
J Drug Target; 2000; 7(5):373-82. PubMed ID: 10721799
[TBL] [Abstract][Full Text] [Related]
5. Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes.
Yamauchi M; Kusano H; Saito E; Iwata T; Nakakura M; Kato Y; Uochi T; Akinaga S; Aoki N
J Control Release; 2006 Aug; 114(2):268-75. PubMed ID: 16860428
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.
Brignole C; Pagnan G; Marimpietri D; Cosimo E; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):231-5. PubMed ID: 12880987
[TBL] [Abstract][Full Text] [Related]
7. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures.
Semple SC; Klimuk SK; Harasym TO; Dos Santos N; Ansell SM; Wong KF; Maurer N; Stark H; Cullis PR; Hope MJ; Scherrer P
Biochim Biophys Acta; 2001 Feb; 1510(1-2):152-66. PubMed ID: 11342155
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain.
Kilic AC; Capan Y; Vural I; Gursoy RN; Dalkara T; Cuine A; Hincal AA
J Microencapsul; 2005 Sep; 22(6):633-41. PubMed ID: 16401579
[TBL] [Abstract][Full Text] [Related]
9. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1.
Stuart DD; Kao GY; Allen TM
Cancer Gene Ther; 2000 Mar; 7(3):466-75. PubMed ID: 10766353
[TBL] [Abstract][Full Text] [Related]
10. Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides.
Kim SH; Kim EJ; Hou JH; Kim JM; Choi HG; Shim CK; Oh YK
Biomaterials; 2009 Feb; 30(5):959-67. PubMed ID: 19027156
[TBL] [Abstract][Full Text] [Related]
11. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats.
Ponnappa BC; Dey I; Tu GC; Zhou F; Aini M; Cao QN; Israel Y
J Pharmacol Exp Ther; 2001 Jun; 297(3):1129-36. PubMed ID: 11356938
[TBL] [Abstract][Full Text] [Related]
12. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells.
Bijsterbosch MK; Manoharan M; Rump ET; De Vrueh RL; van Veghel R; Tivel KL; Biessen EA; Bennett CF; Cook PD; van Berkel TJ
Nucleic Acids Res; 1997 Aug; 25(16):3290-6. PubMed ID: 9241243
[TBL] [Abstract][Full Text] [Related]
13. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
Hu Q; Bally MB; Madden TD
Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
[TBL] [Abstract][Full Text] [Related]
14. Magnetofection--a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo.
Krötz F; de Wit C; Sohn HY; Zahler S; Gloe T; Pohl U; Plank C
Mol Ther; 2003 May; 7(5 Pt 1):700-10. PubMed ID: 12718913
[TBL] [Abstract][Full Text] [Related]
15. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
16. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects.
Hu Q; Shew CR; Bally MB; Madden TD
Biochim Biophys Acta; 2001 Sep; 1514(1):1-13. PubMed ID: 11513800
[TBL] [Abstract][Full Text] [Related]
17. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells.
Kamps JA; Morselt HW; Swart PJ; Meijer DK; Scherphof GL
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11681-5. PubMed ID: 9326670
[TBL] [Abstract][Full Text] [Related]
18. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
Mui B; Raney SG; Semple SC; Hope MJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
[TBL] [Abstract][Full Text] [Related]
19. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats.
Adrian JE; Kamps JA; Scherphof GL; Meijer DK; van Loenen-Weemaes AM; Reker-Smit C; Terpstra P; Poelstra K
Biochim Biophys Acta; 2007 Jun; 1768(6):1430-9. PubMed ID: 17493581
[TBL] [Abstract][Full Text] [Related]
20. Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes.
Weecharangsan W; Yu B; Zheng Y; Liu S; Pang JX; Lee LJ; Marcucci G; Lee RJ
Mol Pharm; 2009; 6(6):1848-55. PubMed ID: 19725564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
